YMAB 8.58 ▲ 0.12% Live Trading Data - Stocknear
Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Start Trial

    Y-mAbs Therapeutics Inc.

    NASDAQ: YMAB · Real-Time Price · USD
    8.58
    0.01 (0.12%)
    At close: Sep 05, 2025, 3:59 PM
    8.58
    0.00%
    After-hours: Sep 05, 2025, 04:24 PM EDT
    0.12%
    Bid 8.57
    Market Cap 389.86M
    Revenue (ttm) 85.39M
    Net Income (ttm) -22.22M
    EPS (ttm) -0.5
    PE Ratio (ttm) -17.16
    Forward PE -9.22
    Analyst Hold
    Ask 8.59
    Volume 445,257
    Avg. Volume (20D) 911,145.9
    Open 8.56
    Previous Close 8.57
    Day's Range 8.56 - 8.59
    52-Week Range 3.55 - 16.11
    Beta 0.53

    About YMAB

    undefined

    [Read more]
    Industry n/a
    Sector n/a
    IPO Date n/a
    Employees NaN
    Stock Exchange n/a
    Ticker Symbol YMAB
    Website n/a
    Full Company Profile

    Analyst Forecast

    According to 0 analyst ratings, the average rating for YMAB stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

    Stock Forecasts

    Next Earnings Release

    Y-mAbs Therapeutics Inc. is scheduled to release its earnings on Nov 7, 2025, before market opens.
    Analysts project revenue of ... Unlock content with Pro Subscription
    1 month ago
    +103.34%
    Y-MAbs Therapeutics shares are trading higher afte... Unlock content with Pro Subscription
    9 months ago
    -0.77%
    Y-MAbs Therapeutics shares are trading higher after Brookline Capital initiated coverage on the stock with a Buy rating and announced a price target of $17.
    news image

    5 days ago · zacks.com

    Y-mAbs Therapeutics, Inc. (YMAB) Now Trades Above Golden Cross: Time to Buy?

    After reaching an important support level, Y-mAbs Therapeutics, Inc. (YMAB) could be a good stock pick from a technical perspective. YMAB recently experienced a "golden cross" event, which saw its 50-...

    news image

    4 weeks ago · zacks.com

    Y-mAbs Therapeutics, Inc. (YMAB) Reports Q2 Loss, Tops Revenue Estimates

    Y-mAbs Therapeutics, Inc. (YMAB) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of a loss of $0.27. This compares to a loss of $0.21 per share a year ago.

    news image

    4 weeks ago · businesswire.com

    Shareholder Alert: The Ademi Firm Investigates Whether Y-mAbs Therapeutics Inc. is Obtaining a Fair Price for its Public Shareholders

    MILWAUKEE--(BUSINESS WIRE)--The Ademi Firm is investigating Y-mAbs (NASDAQ: YMAB) for possible breaches of fiduciary duty and other violations of law in its transaction with SERB Pharmaceuticals. Clic...

    news image

    4 weeks ago · fool.com

    Y-mAbs (YMAB) Q2 Revenue Falls 14%

    Y-mAbs Therapeutics (YMAB), a biopharmaceutical company focused on developing and commercializing antibody-based cancer therapies, reported its second quarter 2025 results on August 8, 2025. The compa...

    news image

    1 month ago · businesswire.com

    Y-MABS THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Y-mAbs Therapeutics, Inc. - YMAB

    NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Y-mAb...

    news image

    1 month ago · zacks.com

    YmAbs Therapeutics (YMAB) Surges 103.3%: Is This an Indication of Further Gains?

    YmAbs Therapeutics (YMAB) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price i...

    news image

    1 month ago · https://thefly.com

    Y-mAbs Therapeutics upgraded to Equal Weight from Underweight at Morgan Stanley

    Morgan Stanley upgraded Y-mAbs Therapeutics to Equal Weight from Underweight with a price target of $8.60, up from $7, after the company agreed to be acquired by SERB Pharmaceuticals for $8.60 per sha...

    news image

    1 month ago · https://thefly.com

    Y-mAbs Therapeutics downgraded to Hold from Buy at Canaccord

    Canaccord downgraded Y-mAbs Therapeutics to Hold from Buy with a price target of $8.60, down from $26, after the company agreed to be acquired by SERB Pharmaceuticals for $8.60 per share in cash.

    news image

    1 month ago · https://thefly.com

    Y-mAbs Therapeutics downgraded to Perform from Outperform at Oppenheimer

    Oppenheimer analyst Jeff Jones downgraded Y-mAbs Therapeutics without a price target to Perform from Outperform after the company agreed to be acquired by SERB Pharmaceuticals for $8.60 per share in c...

    news image

    1 month ago · https://thefly.com

    Y-mAbs Therapeutics downgraded to Hold from Buy at Brookline

    Brookline analyst Kemp Dolliver downgraded Y-mAbs Therapeutics to Hold from Buy with an $8.60 price target after the company agreed to be acquired by SERB Pharmaceuticals for $8.60 per share in cash.

    Add to Watchlist